Biologicals in IgE-mediated food allergy.
IgE-mediated food allergy, omalizumab, cow's milk allergy
biological therapy, monotherapy, adjunct to oral immunotherapy
speculation
personalized treatment, best candidate for each treatment, optimal dose and timing
Abstract
A better understanding of the most recent scientific literature in the use of biological therapy in the treatment of patients with IgE-mediated food allergy. A systematic review and meta-analysis demonstrated safety and effectiveness of omalizumab in the treatment of food allergy. The findings support the potential use of omalizumab as a monotherapy or as an adjunct to oral immunotherapy in IgE-mediated cow's milk allergy. The potential use of other biologics in the management of food allergy is subject of speculation. Different biological therapies are under evaluation for food allergic patients. The advance in literature will guide for a personalized treatment in the near future. However, additional research is needed to better understand the best candidate for each treatment, the optimal dose and timing.